Skip to main content
EMBC logo

EMBC · Embecta Corp.

Track EMBC — free
$6.17 +0.02 (+0.33%)
Market Cap
$348.46M
Shares
56.66M
Volume · Nov 18 186.52K Avg daily vol (3M) 1.04M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.15 Open$6.12 Day$6.02–6.26 52W close$2.90–14.64 Avg vol 30d832K Short int5.8M · 10.3% of shares · 6.8d Short vol61% Last earningsAug 7, 2026 DataMar 2022–Nov 2026 Filing10-Q · Aug 7

Up next

Nov 24, 2026 Est · unconfirmed · in 1 wks

Latest documents

2026
Aug 7
Quarterly report 10-Q FY2026 Q3, ended Jun 30
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $271.7M ▼ 8.1% Net income $21.1M ▼ 53.6% Diluted EPS $0.36 ▼ 53.8%
Jul 31
Current report 8-K/A Events of May 15
Current report AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.02B
Trailing 12 months
Net income (TTM)
$87.50M
Trailing 12 months
Revenue growth YoY
-8.1%
Year over year
Operating margin
21.9%
Trailing 12 months
P / E (TTM)
4.2
Trailing earnings · reciprocal yield 23.9%
FCF yield
47.2%
TTM · current market cap
Return on invested capital
24.9%
Trailing 12 months
Net cash
−$1.24B
Latest balance sheet
Dividend yield
5.2%
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
-57.0%
Trailing year
Short interest
10.3%
Latest settlement · 6.8 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Aug 7, 2026
Q3 FY26

TL;DR. Embecta reported Q3 revenue of $271.7M, down 8.1% YoY but improved sequentially by ~$50M, while reaffirming FY2026 revenue guidance and raising its FY2026 adjusted operating margin guide to 23.5%–24.0% and adjusted EPS guide to $1.80–$1.90 after closing the Owen Mumford deal mid-quarter.

Bullish
  • + Raised FY2026 adjusted EPS guidance to $1.80–$1.90 from $1.55–$1.75.
  • + Closed the Owen Mumford acquisition mid-Q3 and is raising M&A contribution guidance.
  • + Sequential improvement: revenue +$50M, GAAP operating income +$14M, and adjusted operating income +$21M vs. Q2.
  • + International revenue grew 11.5% reported (9.7% adjusted constant currency), driven by Latin America and Asia.
Bearish
  • − Total Q3 revenue fell 8.1% YoY (8.9% adjusted constant currency) to $271.7M.
  • − U.S. revenue fell 24.6% YoY in Q3, with greater customer/payer mix impact on net pricing.
  • − GAAP net income fell to $21.1M (EPS $0.36) from $45.5M ($0.78) and adjusted EPS fell to $0.56 from $1.12.
  • − High-end of FY2026 adjusted organic constant currency revenue growth lowered, driven by U.S. customer/payer mix.
  • − Pen needles revenue declined ~18.6% YoY on an adjusted constant currency basis.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +0%
above
Price vs 50-day avg +3%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 28%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −4%
trailing
6-month return +85%
trailing
YTD return −48%
this year
Relative strength +88%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $6 › 200d $6 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +61 funds added
Insider flow Distributing
Net -$37.0K over 90 days · 100% sells
Short interest Falling
10.26% of shares out · ▼ -0.9% MoM · 6.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
322 holders — near 3-yr low, contrarian setup
Squeeze score 76
high risk · 0–100
Fundamentals
Strong
Revenue growth −4%
Y/Y
Gross margin 63%
contracting
EPS growth +21%
Y/Y
Free cash flow $182.4M
Valuation P/E 4.2
below peers
Buyback $91.0M
remaining
Balance sheet $1.2B
net debt
Quant / Vol
risk profile
Very High
Volatility 82%
annualized · 1-yr
Max drawdown −80%
past year
ATR 5.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed May 5, 2026
Share repurchase program · three-year $100M
Previous outlook earlier release · from the Earnings Call filed Mar 31, 2026

Still-open targets the latest release did not restate under the same label.

Debt repayment · during the course of this year $150M
Prior guidance period ended · from the 8-K filed Aug 7, 2026
Impact of Italian Payback Measure (2) (%) · fiscal year 2026 -0.1%
M&A (%) · fiscal year 2026 2.9% – 3.4%
Adjusted Organic Constant Currency Revenue Growth (%) · fiscal year 2026 -10.2% – -8.8%
Guided vs delivered · last 1 settled
Revenues For fiscal year 2024, the Company expects
guided $1.09B – $1.11B
$1.12B Beat +2.6%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+0% Bullish
Price vs 50-day avg
+3% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
28% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $6 › 200d $6 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +61 funds added
Insider flow Distributing
Net -$37.0K over 90 days · 100% sells
Short interest Falling
10.26% of shares out · ▼ -0.9% MoM · 6.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
322 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $3 Now $6 · 28% Range high $15
vs 200-day avg +0% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA and margin non-GAAP $247.5M Nine Months Ended June 30, 2026 —
Adjusted EBITDA Margin non-GAAP 32.8% Nine Months Ended June 30, 2026 —
Adjusted gross profit and margin non-GAAP $453.4M Nine Months Ended June 30, 2026 —
Adjusted Gross Profit Margin non-GAAP 60.1% Nine Months Ended June 30, 2026 —
Adjusted Net Income non-GAAP $91M Nine Months Ended June 30, 2026 —
Adjusted net income and adjusted earnings per diluted share non-GAAP $91M Nine Months Ended June 30, 2026 —
Adjusted Net Income per Diluted share non-GAAP $1.53 Nine Months Ended June 30, 2026 —
Adjusted operating income and margin non-GAAP $197.3M Nine Months Ended June 30, 2026 —
Adjusted Operating Income Margin non-GAAP 26.1% Nine Months Ended June 30, 2026 —
Adjusted Revenues non-GAAP $754.7M Nine Months Ended June 30, 2026 —
Non-GAAP Free Cash Flow non-GAAP $87.9M Nine Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EMBC
Embecta Corp.
this stock
$348.46M -48.2% -3.8% 4.2 10.3%
ISRG
Intuitive Surgical Inc
$147.37B -24.0% +20.5% 51.5 2.0%
BDX
Becton Dickinson & Co
$58.68B — +8.2% 95.3 3.0%
MDLN
Medline Inc.
$49.56B -10.3% +11.5% — 2.9%
ALC
Alcon Inc
$35.60B -6.0% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
322
% held
92.2%
Net QoQ
+1.9M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
179
View
Short & Settlement
Short Interest Falling
Shares short
5.8M
Days to cover
6.8d
Change
-54.7K sh
View
Short Volume
Short vol %
61%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
49.9K
Value
$322.6K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
41.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$37.0K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$1.1B
Net income (FY)
$95.4M
EPS diluted
$1.62
View
Buybacks
Authorized
$100.0M
Remaining
$91.0M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 7, 2026
This year
11
View
Proposed Sales
Value
$36.9K
Shares
6.3K
Filed
Sep 4, 2026
View
Earnings & Events
Webcasts
Last webcast
Aug 7, 2026
View
Investor Relations
Latest news
embecta to Participate in Investo…
Published
Aug 31, 2026
View

Performance

5D 20D 120D MTD YTD
EMBC -4.4% -4.2% +84.7% -1.6% -48.2%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -2.0% +0.6% +87.6% +1.5% -55.6%

Capital returns

Latest dividend
$0.01 / share · ex Aug 27, 2026
Cut 93.3%
Paid (TTM)
$0.32 / share · 4 payouts
Dividend yield (TTM, derived)
5.20%
Full dividend history
Buyback program · as of Aug 7, 2026
Authorized
$100.00M
Spent (derived)
$9.00M
Remaining
$91.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1872789 CUSIP 29082K105 13F (30d) 341 filings 288 filers Visit website Investor relations